Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2

与针对SARS-CoV-2的BNT162b2 mRNA疫苗的抗体反应强度相关的免疫学特征

阅读:1
作者:Takahiro Kageyama ,Shigeru Tanaka ,Keishi Etori ,Koto Hattori ,Kazusa Miyachi ,Tadamichi Kasuya ,Taro Iwamoto ,Kei Ikeda ,Hidetoshi Igari ,Koutaro Yokote ,Hiroshi Nakajima

Abstract

Predictive clinical factors associated with favorable responses to BNT162b2 mRNA vaccine against SARS-CoV-2 have been reported in some studies; however, there is a subgroup with low antibodytiters without well-known clinical factors reducing antibody responses. To clarify the immunological backgrounds that underlie the difference in antibody responses, we analyzed peripheral blood mononuclear cells (PBMCs) of each 20 individuals with a high anti-SARS-CoV-2 antibody titer and a low antibody titer out of 1774 healthcare workers who received BNT162b2 mRNA vaccine. A higher percentage of B cells before vaccination was associated with a higher antibody titer. Among B cells, naïve and transitional B cell frequencies were positively correlated with a higher antibody titer, whereas the frequencies of late memory B cells and plasmablasts were associated with a lower antibody titer. Fold change in the frequency of activated CD8+ T cells upon vaccination was also correlated with high antibody titers.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。